318 related articles for article (PubMed ID: 27943234)
1. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
Zarbo A; Belum VR; Sibaud V; Oudard S; Postow MA; Hsieh JJ; Motzer RJ; Busam KJ; Lacouture ME
Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
[TBL] [Abstract][Full Text] [Related]
3. Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy.
Wen L; Zhao J; Yang Y; Chen W; Bao Y; Zhang J; Wei T; Zhou L; Xi B; Zhang Y; Liang T
J Immunother; 2023 Jul-Aug 01; 46(6):232-235. PubMed ID: 37212789
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
Kejamurthy P; Devi KTR
Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
[TBL] [Abstract][Full Text] [Related]
5. Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report.
Oliel S; Moussa S; Stanciu M; Netchiporouk E
SAGE Open Med Case Rep; 2023; 11():2050313X231213135. PubMed ID: 38033914
[TBL] [Abstract][Full Text] [Related]
6. Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review.
Salazar González F; Quiñones Palacios CA; Manzaneque Gordón A; Mazarico Gallego JM; Díaz A; Molas Ferrer G
Anticancer Drugs; 2024 Mar; 35(3):284-287. PubMed ID: 37948346
[TBL] [Abstract][Full Text] [Related]
7. A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
Medri M; Savoia F; Foca F; Miserocchi A; Quaglino P; Rubatto M; Gullo G; Nardini C; Panasiti V; DE Tursi M; DI Marino P; Brancaccio G; Giunta EF; Napolitano S; Cinotti E; Brusasco M; Stanganelli I;
Ital J Dermatol Venerol; 2023 Dec; 158(6):437-444. PubMed ID: 38015482
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors.
Wan Z; Huang J; Ou X; Lou S; Wan J; Shen Z
An Bras Dermatol; 2024; 99(3):425-432. PubMed ID: 38388337
[TBL] [Abstract][Full Text] [Related]
9. Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction.
Deng J; Chen X; Sun H; Liu Y; Li W; Chen B; Zhao S; Jia K; Wang H; Guo H; Jiang M; Xu Y; He Y; Zhou C
Ann Transl Med; 2020 Jul; 8(14):889. PubMed ID: 32793733
[TBL] [Abstract][Full Text] [Related]
10. Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.
Lai X; Stiff A; Duggan M; Wesolowski R; Carson WE; Friedman A
Proc Natl Acad Sci U S A; 2018 May; 115(21):5534-5539. PubMed ID: 29735668
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy may exacerbated anti-programmed cell death 1 treatment induced vitiligo: A case report.
Chen C; Chang Q; Wang B; Wang Y; Zhang Z; Wang X
Skin Health Dis; 2024 Feb; 4(1):e287. PubMed ID: 38312255
[TBL] [Abstract][Full Text] [Related]
12. Diphenylcyclopropenone-induced vitiligo in a patient with alopecia universalis.
Riad H; Mannai HA; Mansour K; Qaatri KA; Dosari SA; Obaidaly AA; Sultan E
Case Rep Dermatol; 2013; 5(2):225-31. PubMed ID: 24019775
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse effects associated with LAG-3 inhibitor use in cancer treatment: A systematic review.
Ghani H; Khan S; Jamgochian M; Richards B; DeCecco E; Fliorent R; Cheendalla N; Khatri K; Rao B
Skin Health Dis; 2023 Dec; 3(6):e296. PubMed ID: 38047262
[TBL] [Abstract][Full Text] [Related]
14. Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor-related and conventional.
Imagawa A
J Diabetes Investig; 2021 Jun; 12(6):917-919. PubMed ID: 33098749
[TBL] [Abstract][Full Text] [Related]
15. The evolving landscape of immune-related adverse events that follow immune checkpoint immunotherapy in cancer patients.
Villani AC
Immunol Rev; 2023 Sep; 318(1):4-10. PubMed ID: 37632320
[No Abstract] [Full Text] [Related]
16. Onset of Vitiligo Within Patients Receiving Immune Checkpoint Inhibitors: An Evidence-Based Review.
Bagit A; Sachdeva M; Sood S; Akuffo-Addo E; Alli S; Maliyar K; Georgakopoulos JR; Mufti A; Yeung J
J Cutan Med Surg; 2024 Mar; ():12034754241239250. PubMed ID: 38468185
[No Abstract] [Full Text] [Related]
17. Alopecia areata in a patient with cytotoxic T lymphocyte antigen-4 haploinsufficiency successfully treated with topical delgocitinib ointment.
Senda A; Shibuya R; Miyake T; Nomura T; Dainichi T; Kabashima K
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e51-e53. PubMed ID: 37595288
[No Abstract] [Full Text] [Related]
18. Interleukin-17 Monoclonal Antibody Successfully Treated Psoriasiform Drug Eruption Induced by Immune Checkpoint Inhibitors: A Case Report and Review of Literature.
Li M; Yu S; Zhang G; Xie Y; Wei JC
Dermatitis; 2023 Nov; ():. PubMed ID: 37934278
[No Abstract] [Full Text] [Related]
19. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
Behling J; Kaes J; Münzel T; Grabbe S; Loquai C
Melanoma Res; 2017 Apr; 27(2):155-158. PubMed ID: 27977496
[TBL] [Abstract][Full Text] [Related]
20. Resistance to PD1/PDL1 checkpoint inhibition.
O'Donnell JS; Long GV; Scolyer RA; Teng MW; Smyth MJ
Cancer Treat Rev; 2017 Jan; 52():71-81. PubMed ID: 27951441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
